| Market Cap | 8.59M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -8.81M | Forward P/E | -0.49 | EPS next Y | - | 50D Avg Chg | -19.00% |
| Sales | 610 | PEG | - | EPS past 5Y | - | 200D Avg Chg | -64.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -88.00% |
| Recommedations | 2.00 | Quick Ratio | 0.49 | Shares Outstanding | 100.08M | 52W Low Chg | 13.00% |
| Insider Own | 35.89% | ROA | -107.06% | Shares Float | 64.07M | Beta | 1.15 |
| Inst Own | 0.01% | ROE | - | Shares Shorted/Prior | 2.69M/534.87K | Price | 0.08 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 7,698,827 | Target Price | - |
| Oper. Margin | -1,678,791.00% | Earnings Date | Apr 24 | Volume | 2,234,365 | Change | -3.54% |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
